Drug Bandit Admits to Heists at Lilly, Glaxo Warehouses
Sep 11, 2013
Eli Lilly and Co and partner Boehringer Ingelheim announced on Wednesday that the FDA has declined to approve the experimental diabetes drug empagliflozin, citing previously observed quality issues at a Boehringer facility where the drug would be manufactured.
In the race to switch multiple sclerosis patients to a new, patent-protected version of its top selling drug, Copazone, Teva Pharmaceutical Industries is using records from its 24-hour support hotline in the U.S. to personally contact 85,000 patients.
Italian antitrust authorities have fined Novartis and Roche Holdings a total of $250 million for allegedly colluding to prevent the use of Roche’s Avastin cancer drug as a treatment for eye disease, in favor of a more expensive drug.
The draft guidance provides a checklist for manufacturers to meet before scientific or medical journals be distributed to physicians
A late stage study has proved Eli Lilly's experimental, once-weekly medicine for type 2 diabetes is as effective in lowering blood sugar as market-leading Victoza from Novo Nordisk.
Oxygen Biotherapeutics announces that FDA completed its review of nonclinical submission of Oxycyte
03/04/2014QbD Included in DCAT Week '14 Lineup
DCAT Week '14, held March 10-14 in NYC, will address quality by design in a session titled, Quality by Design: Client, Contractor, and Regulatory Perspectives with Case Studies.
Global Pharma Congress 2014, held May 28-29th in Shanghai, will now integrate three influential conferences under one roof - Pharma QbD, Pharma Cold Chain and NDDS.
Canada's regulatory authority, Health Canada, has mandated that all pharma companies globally applying for approval to sell drugs in Canada now need to submit quality summary documents and certifications.
Olympus Biotech initiating aggressive transaction process to find a buyer